Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bulevirtide registry study in chronic hepatitis D
NL-OMON60236Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of bulevirtide in Chronic Viral Hepatitis B With Delta-Agent (2 cohorts), sponsored by Gilead Sciences. Primary endpoint: Exposure-adjusted incidence of participants with liver-related events. Started Dec 2022; status: completed.
02
Drugs
bulevirtide
03
Conditions
Chronic Viral Hepatitis B With Delta-Agent
Beyond the preview
Go deeper on NL-OMON60236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60236.